Skip to main content
. 2023 May 12;13(5):e069770. doi: 10.1136/bmjopen-2022-069770

Figure 5.

Figure 5

Proportion of patients at 1-year follow-up for each year 2006–2019 treated with statins, ezetimibe, ACEi or ARB, beta blockers, antiplatelet (acetylsalicylic acid or P2Y12-receptor antagonists) or anticoagulant therapy (warfarin or direct oral anticoagulants). ACEi, ACE inhibitor; ARB, angiotensin receptor blocker.